Clinical Trial News and Research

RSS

Gen-Probe commences its PROGENSA PCA3 assay clinical trial

Gen-Probe Incorporated announced today that the Company has begun a clinical trial intended to secure U.S. regulatory approval of its PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

28 Aug 2009

Infectious Disease Research Institute commences clinical trial of its leishmaniasis vaccine in Sudan

IDRI (Infectious Disease Research Institute) announced today the start of a clinical trial in Sudan to test its leishmaniasis vaccine candidate for the treatment of post kala-azar dermal leishmaniasis (PKDL), a complication of visceral leishmaniasis (VL) which is observed in 50% of patients treated for VL in the country, predominantly affecting children.

28 Aug 2009

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Cardium Therapeutics today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.

28 Aug 2009

Ochsner Medical Center selected to participate as an FDA investigative site in the PARTNER clinical trial

On Tuesday, August 11, 2009, an 82-year old New Orleans resident with severe aortic stenosis successfully had a heart valve replaced at Ochsner Medical Center using the same technique as angioplasty, a far cry from the traditional open heart procedure. Patients who are considered high-risk or non-operable for conventional open heart valve surgery now have a potential new research option available regionally only through The John Ochsner Heart & Vascular Institute.

28 Aug 2009

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

28 Aug 2009

Geron provides additional comments on the recent clinical hold of Spinal Cord Injury IND

Geron Corporation today provided additional comments on the recent clinical hold on its Spinal Cord Injury IND.

27 Aug 2009

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Medgenics is pleased to announce that one of the patients, who was treated with the Company’s EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company’s phase I/II anemia trial in Israel.

27 Aug 2009

New Associate Director of Business Development appointed by ERT

ERT, announced the appointment of a new Associate Director of Business Development - Japan, Miki Stevens. In this new role, Ms. Stevens will work with ERT's Japanese partner, Site Support Institute (SSI), to facilitate sales activities and to provide enhanced in-country support of Japanese sponsors and clinical trial sites.

27 Aug 2009

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Bristol-Myers Squibb Company announced today that clinical data added to the labeling for ORENCIA (abatacept) support use of ORENCIA for patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

27 Aug 2009

CardioMEMS raises $22.1M to fund clinical trial of its heart failure pressure measurement system

CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.

27 Aug 2009

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.

27 Aug 2009

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today presented its consolidated half-year accounts to June 30, 2009.

27 Aug 2009

Angeion Corporation announces financial results for third-quarter fiscal 2009

For the 2009 third quarter, Angeion posted a net loss of $173,000, or $0.04 per diluted share, on revenues of $6.2 million. This represents a sequential improvement from a 2009 second-quarter net loss of $225,000, or $0.05 per diluted share, also on revenues of $6.2 million.

27 Aug 2009

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

Endocyte, Inc., a cancer drug discovery and development company, today announced it has received a milestone payment from Bristol-Myers Squibb Company (NYSE: BMY). This payment was triggered by the commencement of a Phase II clinical trial for an epothilone-folate anti-cancer agent identified through the collaboration between Endocyte and Bristol-Myers Squibb scientists.

26 Aug 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

SIRO Clinpharm and CambReg Regulatory Services announces their alliance

SIRO Clinpharm, a leading Indian MNC CRO, and CambReg Regulatory Services, a UK-based pan-European regulatory services provider, announced today the formation of an exclusive strategic alliance to help companies register their products in the European market.

26 Aug 2009

Initial abstract for the clinical study of PLC's RenalGuard System published

PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that the initial abstract for the investigator-sponsored clinical study of its RenalGuard System(TM) has been published, in advance of the annual meeting of the European Society of Cardiology, August 29 - September 2, 2009 in Barcelona, Spain, on the ESC website.

26 Aug 2009

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6.

26 Aug 2009

AOFAS announces results of clinical trials with the STAR ankle replacement device

Charles L. Saltzman, MD, newly-elected president of the American Orthopaedic Foot & Ankle Society (AOFAS), presented the results of a groundbreaking study at the recent AOFAS 2009 Annual Summer Meeting in Vancouver, British Columbia, Canada.

26 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

Clinical Trial News and Research

Gen-Probe commences its PROGENSA PCA3 assay clinical trial

Infectious Disease Research Institute commences clinical trial of its leishmaniasis vaccine in Sudan

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Ochsner Medical Center selected to participate as an FDA investigative site in the PARTNER clinical trial

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

Geron provides additional comments on the recent clinical hold of Spinal Cord Injury IND

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

New Associate Director of Business Development appointed by ERT

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

CardioMEMS raises $22.1M to fund clinical trial of its heart failure pressure measurement system

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

Angeion Corporation announces financial results for third-quarter fiscal 2009

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

SIRO Clinpharm and CambReg Regulatory Services announces their alliance

Initial abstract for the clinical study of PLC's RenalGuard System published

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

AOFAS announces results of clinical trials with the STAR ankle replacement device

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery